CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: GlobeNewswire
-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70- -Expanding trials of CTX112 into autoimmune disease, with planned initiation in the first half of 2024, in addition to the ongoing clinical trial in B-cell malignancies- -Expanding trials of CTX131 into hematologic malignancies, including T- and B-cell malignancies, in addition to the ongoing clinical trial in solid tumors- -Next-generation candidates manufactured at internal GMP facility exhibit increased manufacturing robustness and scalability- ZUG, Switzerland and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T cell product candidates. The Company’s first
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is CRISPR Therapeutics Stock Yesterday's News? [Yahoo! Finance]Yahoo! Finance
- How Early Zugo-cel Data and Lilly Partnership Could Impact CRISPR Therapeutics (CRSP) Investors [Yahoo! Finance]Yahoo! Finance
- 3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (NASDAQ:CRSP) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $80.00 price target on the stock.MarketBeat
- CRISPR Therapeutics (NASDAQ:CRSP) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $86.00 price target on the stock.MarketBeat
CRSP
Earnings
- 11/10/25 - Beat
CRSP
Sec Filings
- 12/23/25 - Form 4
- 12/22/25 - Form 4
- 12/22/25 - Form 144
- CRSP's page on the SEC website